The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia

International Journal of Clinical Practice, Supplement

Volumn , Issue 127, 2002, Pages 20-36

  Rosler M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Behaviour; Cholinesterase inhibitors; Dementia; Donepezil; Galantamine; NeuroPsychiatric Inventory (NPI); Rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; BROMPERIDOL; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RISPERIDONE; RIVASTIGMINE;

ALZHEIMER DISEASE; ANXIETY; APATHY; BEHAVIOR; BEHAVIOR DISORDER; BRAIN REGION; CLINICAL TRIAL; DELUSION; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; HALLUCINATION; HUMAN; INSOMNIA; LEWY BODY; MULTIINFARCT DEMENTIA; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; REVIEW; SLEEP DISORDER; SYMPTOM; VOMITING;

BEHAVIORAL SYMPTOMS; CARBAMATES; CHOLINESTERASE INHIBITORS; DEMENTIA; GALANTAMINE; HUMANS; INDANS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; TREATMENT OUTCOME;

EID: 0036063168     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Epidemiology and pathophysiology of Alzheimer's disease
2. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease
3. Typical clinical features
4. Measuring response to treatments in Alzheimer's disease: What constitutes meaningful change?
5. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease
6. The evolution of psychiatric symptoms in Alzheimer's disease: A natural history study
7. The spectrum of behavioral changes in Alzheimer's disease
8. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis
9. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease
10. Dementia with Lewy bodies
11. Risk of dementia in Parkinson's disease: A community-based, prospective study
12. Vascular dementia: A contemporary review of epidemiology, diagnosis, prevention, and treatment
13. Vascular dementia: Dead or alive?
14. The cholinergic hypothesis of geriatric memory dysfunction
15. Selective loss of central cholinergic neurons in Alzheimer's disease
16. Ageing: The cholinergic hypothesis of cognitive decline
17. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
18. Alzheimer's disease
19. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease
20. Effect of specific muscarinic M2 receptor antagonist on carbachol induced
21. Mental and behavioral disturbances in dementia: Findings from the cache county study on memory in aging
22. Topographical distribution of neurochemical changes in Alzheimer's disease
23. Effects of two-year treatment with cholinesterase inhibitor rivastigmine on behavioral symptoms in Alzheimer's disease
24. Orbitofrontal and anterior cingulated cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease
25. Costs of dementia and dementia care: A review
26. Alzheimer's disease in the UK: Burden of disease and future care
27. Quality of life assessment in dementia drug development
28. Anxiety and depressive disorders in adult children caring for demented parents
29. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale
30. Family, Alzheimer's disease and negative symptoms
31. Determinants of carer stress in Alzheimer's disease
32. Relation between severity of Alzheimer's disease and costs of caring
33. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
34. Incontinence and troublesome behaviors predict institutionalization in dementia
35. The economic benefits of delaying progression in Alzheimer's disease using cholinesterase inhibitors
36. Potential savings in the cost of caring for Alzheimer's disease: Treatment with rivastigmine
37. Theories behind existing scales for rating behavior in dementia
38. Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia
39. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action a hypothesis
40. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients
41. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
42. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up
43. Behavior - The forgotten domain in Alzheimer's disease: Issues in clinical management
44. The pharmacovigilance of olanzapine: Results of a post-marketing surveillance study on 8858 patients in England
45. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review
46. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
47. Selectivity of cholinesterase inhibition
48. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of US multicentre, randomized, double-blind, placebocontrolled trial
49. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial
50. A 5-month, randomized, placebo-controlled trial of galantamine in AD
51. Strategies for analysing behavioral data in clinical trials involving patients with Alzheimer's disease
52. Development of a rating scale for primary depressive illness
53. Cornell scale for depression in Dementia
54. Agitated behaviors in the elderly. I. A conceptual review
55. The behavior rating scale for Dementia of the consortium to establish a registry for Alzheimer's disease
56. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment
57. The Gottfries-Bråne-Steen scale: Validity, reliability and application in anti-dementia drug trials
58. CERAD behaviour rating scale for dementia
59. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
60. The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease
61. Clinical global measure of dementia: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
62. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors
63. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
64. Donepezil improves cognition and global function in Alzheimer's disease
65. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
66. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild-moderate AD
67. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease
68. Effects of donepezil on emotional/behavioural symptoms in Alzheimer's disease patients
69. A randomised double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting
70. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
71. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
72. Donepezil in dementia with Lewy bodies: Treatment and withdrawal
73. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
74. Donepezil for behavioural disorders associated with Lewy bodies: A case series
75. Behavioral complications associated with donepezil
76. Violent behavior associated with donepezil
77. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome
78. Adverse effects associated with the use of donepezil in general practice in England
79. Extrapyramidal side effects in a patient treated with risperidone plus donepezil
80. Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patient with probable dementia with Lewy bodies
81. Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons
82. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study
83. Comparison of the tolerability, ease of use and efficacy of donepezil and rivastigmine in AD patients
84. Aricept-induced nightmares in Alzheimer's disease: 2 Case reports
85. Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community
86. Pharmacological evaluation of phenylcarbamates as CNS-selective acetylcholinesterase inhibitors
87. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
88. Efficacy of rivastigmine in DLB: A randomized double-blind, placebo-controlled international study
89. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomised placebo-controlled international study using the cognitive drug research computerised assessment system
90. Effects of rivastigmine on behavioral symptoms in nursing home patients with Alzheimer's disease
91. Rivastigmine provides behavioral benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial
92. Behavioral and cognitive benefits of rivastigmine in nursing home patients with Alzheimer's disease and related dementias: A 26-week follow-up
93. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial
94. Dementia with lewy bodies treated with rivastigmine: Effects on cognition, neuropsychiatric symptoms, and sleep
95. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial
96. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease
97. Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up
98. Treatment of symptoms specific to patients with subcortical vascular dementia: An open label pilot study comparing rivastigmine and cardioaspirin
99. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
100. A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of coadministration of rivastigmine with risperidone in dementia patients with behavioral disturbances
101. Galantamine is an allosterically potentiating ligand
102. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease
103. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
104. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial
105. Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease
106. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial
107. Galanthamine's clinical benefits are not offset by sleep disturbance: A 3-month placebo-controlled study in patients with Alzheimer's disease
108. Response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression
109. Metrifonate benefits cognitive, behavioural, and global function in patients with Alzheimer's disease
110. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
111. Distribution of butyrylcholinesterase in human amygdala and hippocampal formation
112. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease
113. Differential increase in cerebrospinal fluidacetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
114. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine
115. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment
116. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - A study of molecular forms
117. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
118. Butyrylcholinesterase in the life cycle of amyloid plaques
119. Cholinesterase inhibitors: From the Calabar bean to Alzheimer therapy
120. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
121. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
122. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action
123. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain
124. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia